Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 1Liver Cirrhosis 1Lennox Gastaut Syndrome 1Epilepsies, Myoclonic 1

Interventions

Specimen Handling 3Magnetic Resonance Spectroscopy 3Cisplatin 3Letrozole 2Immune Checkpoint Inhibitors 2Imatinib Mesylate 2Human Papillomavirus Recombinant Vaccine nonavalent 2Diosmin 2Carboplatin 2Azacitidine 2venetoclax 1trametinib 1toripalimab 1tocilizumab 1sofosbuvir-velpatasvir drug combination 1semaglutide 1ruxolitinib 1rozanolixizumab 1rasburicase 1radium Ra 223 dichloride 1pyrotinib 1pirtobrutinib 1oxycodone-acetaminophen 1obinutuzumab 1nirogacestat 1niraparib 1nilotinib 1naldemedine 1idelalisib 1human papillomavirus vaccine, L1 type 16, 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Cannabidiol × 30 days × Clear all
NCT05044819 2026-06-01

Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution

Jazz Pharmaceuticals

Phase 4 Active not recruiting
154 enrolled

Epilepsies, Myoclonic, Liver Cirrhosis, Tuberous Sclerosis, Lennox Gastaut Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡